Insulin sensitivity can be measured by procedures such as the hyperinsulinemic euglycemic clamp or by using surrogate indices. Chronic kidney disease (CKD) and obesity may differentially affect these measurements because of changes in insulin kinetics and organ-specific effects on insulin sensitivity. In a cross-sectional study of 59 subjects with nondiabetic CKD [estimated glomerular filtration rate: (GFR) <60 ml·min·1.73 m] and 39 matched healthy controls, we quantified insulin sensitivity by clamp (SI), oral glucose tolerance test, and fasting glucose and insulin. We compared surrogate insulin sensitivity indices to SI using descriptive statistics, graphical analyses, correlation coefficients, and linear regression. Mean age was 62.6 yr; 48% of the participants were female, and 77% were Caucasian. Insulin sensitivity indices were 8-38% lower in participants with vs. without CKD and 13-59% lower in obese compared with nonobese participants. Correlations of surrogate indices with SI did not differ significantly by CKD or obesity status. Adjusting for SI in addition to demographic factors, Matsuda index was 15% lower in participants with vs. without CKD ( = 0.09) and 36% lower in participants with vs. without obesity ( = 0.0001), whereas 1/HOMA-IR was 23% lower in participants with vs. without CKD ( = 0.02) and 46% lower in participants with vs. without obesity ( < 0.0001). We conclude that CKD and obesity do not significantly alter correlations of surrogate insulin sensitivity indices with SI, but they do bias surrogate measurements of insulin sensitivity toward lower values. This bias may be due to differences in insulin kinetics or organ-specific responses to insulin.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5374297PMC
http://dx.doi.org/10.1152/ajpendo.00394.2016DOI Listing

Publication Analysis

Top Keywords

insulin sensitivity
12
chronic kidney
8
kidney disease
8
hyperinsulinemic euglycemic
8
euglycemic clamp
8
disease obesity
4
obesity bias
4
bias surrogate
4
surrogate estimates
4
insulin
4

Similar Publications

Current Perspectives of Diabetic Dyslipidemia and Treatment Modalities.

Curr Med Chem

January 2025

Cukurova University, Faculty of Medicine, Division of Endocrinology, Adana, Turkey.

Introduction: Diabetes mellitus is associated with an increased risk of atherosclerosis related to dyslipidemia. Although the terms hyperlipidemia and Diabetes Mellitus [DM] or diabetic dyslipidemia are interrelated to each other, these two conditions have some differences.

Aim: This study aimed to highlight possible mechanisms of hyperlipidemia and/or dyslipidemia in diabetic patients, which can be treated with available and newer hypolipidemic drugs.

View Article and Find Full Text PDF

HDL-associated vitamin D binding protein levels are inversely associated with necrotic plaque burden in psoriasis.

Atheroscler Plus

March 2025

Section of Inflammation and Cardiometabolic Diseases, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA.

Background And Aims: Vitamin D binding protein (DBP) serves a dual function as a vitamin D carrier and actin scavenger. Free DBP is present in high concentrations in serum, while a smaller pool is bound to lipoproteins like HDL and VLDL. The role of DBP's interaction with lipoproteins remains unclear.

View Article and Find Full Text PDF

Alternative splicing is a post-transcriptional process resulting in multiple protein isoforms from a single gene. Abnormal splicing may lead to metabolic diseases, including type 2 diabetes mellitus (T2DM). To identify the splicing factor expression that predicts T2DM remission in coronary heart disease (CHD) patients, we identified newly diagnosed T2DM at baseline ( = 190) from the CORDIOPREV study.

View Article and Find Full Text PDF

Mice with genetic ablation of PI3Kγ are protected from diet-induced obesity. However, the cell type responsible for PI3Kγ action in obesity remains unknown. We generated mice with conditional deletion of PI3Kγ in neurons using the nestin promoter to drive the expression of the Cre recombinase (PI3Kγ mice) and investigated their metabolic phenotype in a model of diet-induced obesity.

View Article and Find Full Text PDF

The onset of menopause usually occurs between the ages of 48 and 52, leading to diverse symptoms in various body systems due to a decrease in estrogen level. Visceral obesity and diminished estrogen level during the menopausal phase are associated with unfavorable metabolic changes, resulting in insulin resistance and increased risk of type 2 diabetes mellitus (T2DM). Owing to the increase in the incidence and prevalence of T2DM in recent decades, it is important to identify predisposing factor such as menopausal age to improve T2DM prevention and management.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!